Start Date
September 30, 2022
Primary Completion Date
September 30, 2024
Study Completion Date
December 31, 2024
ENX-101
Adjunctive treatment to current antiseizure medication
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York
Montefiore Medical Center, The Bronx
University of Rochester, Rochester
University of Pittsburgh, Pittsburgh
Mid-Atlantic Epilepsy and Sleep Center, Bethesda
University of Maryland Medical Center, Baltimore
University of Virginia, Charlottesville
Duke University School of Medicine, Durham
Atrium Health, Chapel Hill
DJL Clinical Research, Rock Hill
Emory University School of Medicine, Atlanta
University of Florida Research Institute of Orlando, Gainesville
Florida Hospital, Orlando
Comprehensive Neurology Clinic, Orlando
Royal Care Medical Research Corporation, Miami
University of Miami, Miami
D&H National Research Centers, Miami
S&G Research Center Corp., Miami
Saint Joseph Health System, Lexington
Thomas Jefferson University, Philadelphia
NeuroScience Research Center, LLC, Canton
University of Michigan, Ann Arbor
SRI International, Plymouth
Oakland University William Beaumont School of Medicine, Farmington Hills
OSF HealthCare Illinois Neurological Institute, Peoria
Advanced Clinical Research Center, Bridgeton
Washington University School of Medicine, St Louis
University of Kansas, Kansas City
Somnos Clinical Research/Neurology Associates, Lincoln
Mt. Olympus Medical Research, Sugar Land
University of Colorado, Aurora
Barrow Neurological Institute, Phoenix
University of Arizona, Tucson
Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center, Downey
Hawaii Pacific Neuroscience, Honolulu
Maine Medical Partners Neurology, Scarborough
Northeast Regional Epilepsy Group, Hackensack
Institute of Neurology and Neurosurgery at Saint Barnabas LLC, Livingston
Lead Sponsor
Engrail Therapeutics INC
INDUSTRY